Progreseffects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk

Molecular Medicine Reports

Volumn 7, Issue 3, 2013, Pages 887-892

  Liarmakopoulos, Emmanouil ^a   Theodoropoulos, George ^b   Vaiopoulou, Anna ^c   Rizos, Spyros ^a   Aravantinos, Gerasimos ^d   Kouraklis, Gregory ^e   Nikiteas, Nikolaos ^e   Gazouli, Maria ^c  

^a TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d Agioi Anargyroi Oncology Hospital   (Greece)

^e LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

Gastric cancer; SDF 1; Single nucleotide polymorphisms; Survivin

Indexed keywords

GENOMIC DNA; STROMAL CELL DERIVED FACTOR 1; SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; STOMACH CANCER; TUMOR DIFFERENTIATION; AGED; DISEASE PREDISPOSITION; GENETICS; MIDDLE AGED; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHEMOKINE CXCL12; DISEASE SUSCEPTIBILITY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS;

EID: 84873185011     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1247     Document Type: Article

References (71)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010.
2. Noffsinger A and Waxman I: Preinvasive neoplasia in the stomach: diagnosis and treatment. Clin Gastroenterol Hepatol 9:1018-1023, 2007.
3. Resende C, Ristimäki A and Machado JC: Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 1:34-39, 2010.
4. Venkateshwari A, Krishnaveni D, Venugopal S, Shashikumar P, Vidyasagar A and Jyothy A: Helicobacter pylori infection in relation to gastric cancer progression. Indian J Cancer 48:94-98, 2011.
5. Loh M, Koh KX, Yeo BH, et al: Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer 45:2562-2568, 2009.
6. Gao L, Nieters A and Brenner H: Cell proliferation-related genetic polymorphisms and gastric cancer risk: systematic review and meta-analysis. Eur J Hum Genet 17:1658-1667, 2009.
7. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T and Honjo T: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 261:600-603, 1993. (Pubitemid 23278369)
8. Nagasawa T, Kikutani H and Kishimoto T: Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 91:2305-2309, 1994. (Pubitemid 24092092)
9. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A and Springer TA: A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184:1101-1109, 1996. (Pubitemid 26313567)
10. Bleul CC, Farzan M, Choe H, et al: The lymphocyte chemoattractant SDF-1 is a ligand for LELESTR/fusin and blocks HIV-1 entry. Nature 382:829-833, 1996. (Pubitemid 26299570)
11. Tachibana K, Hirota S, Iizasa H, et al: The chemokine receptor CXCRCR4 is essential for vascularization of the gastrointestinal tract. Nature 393:591-594, 1998. (Pubitemid 28319250)
12. Vandercappellen J, Van Damme J and Struyf S: The role of CXC chemokines and their receptors in cancer. Cancer Lett 267:226-244, 2008.
13. Kucia M, Reca R, Miekus K, et al: Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23:879-894, 2005. (Pubitemid 41170944)
14. Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F and Ren GS: Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res 29:31, 2010.
15. Watanabe MA, de Oliveira Cavassin GG, Orellana MD, Milanezi CM, Voltarelli JC, Kashima S and Covas DT: SDF-1 gene polymorphisms and syncytia induction in Brazilian HIV-1 infected individuals. Microb Pathog 35:31-34, 2003. (Pubitemid 36809187)
16. Dean M, Carrington M and O'Brien SJ: Balanced polymorphism selected by genetic versus infectious human disease. Annu Rev Genomics Hum Genet 3:263-292, 2002. (Pubitemid 35217438)
17. Voevodin A, Samilchuk E and Dashti S: Frequencies of SDF-1 chemokine, CCRCCRCCR-5 and CCRCCRCCR-2 chemokine receptor gene alleles conferring resistance to human immunodeficiency virus type 1 and AIDS in Kuwaitis. J Med Virol 58:54-58, 1999. (Pubitemid 29172121)
18. Winkler C, Modi W, Smith MW, et al: Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279:389-393, 1998.
19. Sei S, O'Neill DP, Stewart SK, et al: Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma. Cancer Res 61:5028-5037, 2001. (Pubitemid 32681531)
20. Ide A, Kawasaki E, Abiru N et al: Stromal-cell derived factor-1 chemokine gene variant is associated with type 1 diabetes age at onset in Japanese population. Hum Immunol 64:973-978, 2003. (Pubitemid 37210849)
21. Hassan S, Baccarelli A, Salvucci O and Basik M: Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res 14:446-454, 2008. (Pubitemid 351226112)
22. Khademi B, Razmkhah M, Erfani N, Gharagozloo M and Ghaderi A: SDF-1 and CCR5 genes polymorphism in patients with head and neck cancer. Pathol Oncol Res 14:45-50, 2008.
23. Hirata H, Hinoda Y, Kikuno N, et al: CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility. Clin Cancer Res 13:5056-5062, 2007. (Pubitemid 47502070)
24. Nahon P, Sutton A, Rufat P, et al: Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis C virus-related cirrhosis. World J Gastroenterol 14:713-719, 2008. (Pubitemid 351325053)
25. Razmkhah M, Doroudchi M, Ghayumi SM, Erfani N and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer 49:311-315, 2005. (Pubitemid 41139143)
26. Coelho A, Calcada C, Catarino R, Pinto D, Fonseca G and Medeiros R: CXCLCL12-3' A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy? Cancer Immunol Immunother 55:639-643, 2006.
27. Razmkhah M, Talei AR, Doroudchi M, Khalili-Azad T and Ghaderi A: Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett 225:261-266, 2005. (Pubitemid 40835873)
28. Dimberg J, Hugander A, Lofgren S and Wagsater D: Polymorphism and circulating levels of the chemokine CXCLCL12 in colorectal cancer patients. Int J Mol Med 19:11-15, 2007.
29. Hidalgo-Pascual M, Galan JJ, Chaves-Conde M, et al: Analysis of CXCL12 3'UTR G>A polymorphism in colorectal cancer. Oncol Rep 18:1583-1587, 2007.
30. Theodoropoulos GE, Panoussopoulos GS, Michalopoulos NV, et al: Analysis of the stromal cell-derived factor 1-3'A gene polymorphism in pancreatic cancer. Mol Med Report 3:693-698, 2010.
31. Ambrosini G, Adida C and Alteri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921, 1997. (Pubitemid 27353455)
32. Deveraux QL and Reed JC: IAP family proteins - suppressors of apoptosis. Genes Dev 13:239-252, 1999. (Pubitemid 29095796)
33. Li F, Ambrosini G, Chu EY, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580-584, 1998. (Pubitemid 28563719)
34. Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542-547, 2001. (Pubitemid 33127139)
35. Liston P, Fong WG and Korneluk RG: The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22:8568-8580, 2003. (Pubitemid 38019194)
36. Thompson CB: Apoptosis is the pathogenesis and treatment of disease. Science 267:1456-1462, 1995.
37. Raff M: Cell suicide for beginners. Nature 396:119-122, 1998. (Pubitemid 28523602)
38. Tamm I, Wang Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases and anticancer drugs. Cancer Res 58:5315-5320, 1998. (Pubitemid 28551107)
39. Asanuma K, Moriai R, Yajima T, et al: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204-1209, 2000.
40. Kawasaki H, Toyoda M, Shinohara H, et al: Expression of survivin correlates with apoptosis, proliferation and angiogenesis during human colorectal tumorigenesis. Cancer 91:2026-2032, 2001. (Pubitemid 32476366)
41. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61-70, 2008.
42. Chen WC, Liu Q, Fu JX and Kang SY: Expression of survivin and its significance in colorectal cancer. World J Gastroenterol 10:2886-2889, 2004. (Pubitemid 39303012)
43. Falleni M, Pellegrini C, Marchetti A, et al: Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 200:620-626, 2003. (Pubitemid 36987311)
44. Fields AC, Cotsonis G, Sexton D, Santoianni R and Cohen C: Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters and outcome. Mod Pathol 17:1378-1385, 2004. (Pubitemid 39472993)
45. Liu BB and Wang WH: Survivin and pancreatic cancer. World J Clin Oncol 2:164-168, 2011.
46. Wang W, Luo H and Wang A: Expression of survivin and correlation with PCNA in osteosarcoma. J Surg Oncol 93:578-584, 2006. (Pubitemid 43806994)
47. Altieri DC, Marchisio PC and Marchisio C: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327-1333, 1999.
48. Xu Y, Fang F, Ludewig G, Jones G and Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527-537, 2004. (Pubitemid 39244331)
49. Borbély AA, Murvai M, Szarka K, et al: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60:303-306, 2007. (Pubitemid 46447748)
50. Jang JS, Kim KM, Kang KH, et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60:31-39, 2008. (Pubitemid 351434465)
51. Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S and Gazouli M: Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 39:976-980, 2010.
52. Yang L, Zhu H, Zhou B, et al: The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 54:1021-1028, 2008.
53. Cheng ZJ, Hu LH and Huang SJ: Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng 27:258-263, 2008 (In Chinese).
54. Sobin LH and Wittekind C: UICC TNM Classification of Malignant Tumours. 5th edition, Wiley-Liss, New York, NY, 1997.
55. Juarez J, Bendall L and Bradstock K: Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Res 10:1245-1259, 2004. (Pubitemid 38425904)
56. Iwasa S, Yanagawa T, Fan J and Katoh R: Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis. Anticancer Res 29:4751-4758, 2009.
57. Ishigami S, Natsugoe S, Okumura H, et al: Clinical implication of CXCL12 in gastric cancer. Ann Surg Oncol 14:3154-3158, 2007. (Pubitemid 47594282)
58. Woo IS, Hong SH, Byun JH, Kang JH, Jeon HM and Choi MG: Circulating stromal cell derived factor-1 is predictive of distant metastasis in gastric carcinoma. Cancer Invest 26:256-261, 2008. (Pubitemid 351329003)
59. Zhao BC, Wang ZJ, Mao WZ, et al: CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol 17:2389-2396, 2011.
60. Wang YH, Chiou HY, Lin CT, et al: Association between survivin gene promoter-31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 73:670-674, 2009.
61. Xu Y, Fang F, Ludewig G, et al: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:419-429, 2004. (Pubitemid 38981976)
62. Xang X, Xiong G, Chen X, et al: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 135:1341-1349, 2009.
63. Gazouli M, Tzanakis N, Rallis G, et al: Survivin-31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 24:145-150, 2009.
64. Qin C, Cao Q, Li P, et al: Functional promoter-31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One 7:e28829, 2012.
65. Yazdani N, Sayahpour FA, Haghpanah V, et al: Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 208:100-103, 2012.
66. Jaiswal PK, Goel A, Mandhani A and Mittal RD: Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep 39:5615-5621, 2012.
67. Zahedi P, Aminimoghaddam S, Sayahpour FA, et al: Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer 22:35-37, 2012.
68. Ma F, Zhang H, Zhai Y, et al: Functional polymorphism-31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among chinese. PLoS One 6:e16748, 2011.
69. Upadhyay R, Khurana R, Kumar S, Ghoshal UC and Mittal B: Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol 18:880-887, 2011.
70. Li Y, Wang J, Jiang F, Lin W and Meng W: Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med Genet 13:1, 2012.
71. Borges BN, Burbano RR and Harada ML: Survivin-31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med 11:189-193, 2011.